49 related articles for article (PubMed ID: 10741701)
1. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
4. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
RamÃrez J; Wu K; Janisch L; Karrison T; House LK; Innocenti F; Cohen EE; Ratain MJ
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1629-32. PubMed ID: 21861128
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
[TBL] [Abstract][Full Text] [Related]
6. In vitro conversion of irinotecan to SN-38 in human plasma.
Shingyoji M; Takiguchi Y; Watanabe-Uruma R; Asaka-Amano Y; Matsubara H; Kurosu K; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
Cancer Sci; 2004 Jun; 95(6):537-40. PubMed ID: 15182436
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.
Ramesh M; Ahlawat P; Srinivas NR
Biomed Chromatogr; 2010 Jan; 24(1):104-23. PubMed ID: 19852077
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen RH; van Alphen RJ; Verweij J; Loos WJ; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2001 Aug; 7(8):2182-94. PubMed ID: 11489791
[TBL] [Abstract][Full Text] [Related]
11. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Santi DV; Ashley GW; Cabel L; Bidard FC
BioDrugs; 2024 Mar; 38(2):171-176. PubMed ID: 38236523
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies.
Shinha K; Nihei W; Ono T; Nakazato R; Kimura H
Biomicrofluidics; 2020 Jul; 14(4):044108. PubMed ID: 34992705
[TBL] [Abstract][Full Text] [Related]
13. Ontogeny of Drug-Metabolizing Enzymes.
Thakur A; Parvez MM; Leeder JS; Prasad B
Methods Mol Biol; 2021; 2342():551-593. PubMed ID: 34272706
[TBL] [Abstract][Full Text] [Related]
14. Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery.
Lamichhane N; Udayakumar TS; D'Souza WD; Simone CB; Raghavan SR; Polf J; Mahmood J
Molecules; 2018 Jan; 23(2):. PubMed ID: 29385755
[TBL] [Abstract][Full Text] [Related]
15. Cancer nanomedicine: a review of recent success in drug delivery.
Tran S; DeGiovanni PJ; Piel B; Rai P
Clin Transl Med; 2017 Dec; 6(1):44. PubMed ID: 29230567
[TBL] [Abstract][Full Text] [Related]
16. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
[TBL] [Abstract][Full Text] [Related]
17. Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.
Manaspon C; Nasongkla N; Chaimongkolnukul K; Nittayacharn P; Vejjasilpa K; Kengkoom K; Boongird A; Hongeng S
Pharm Res; 2016 Dec; 33(12):2891-2903. PubMed ID: 27495180
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Brennan RC; Furman W; Mao S; Wu J; Turner DC; Stewart CF; Santana V; McGregor LM
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1191-8. PubMed ID: 25257509
[TBL] [Abstract][Full Text] [Related]
19. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
May WA; Grigoryan RS; Keshelava N; Cabral DJ; Christensen LL; Jenabi J; Ji L; Triche TJ; Lawlor ER; Reynolds CP
PLoS One; 2013; 8(12):e80060. PubMed ID: 24312454
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Swami U; Goel S; Mani S
Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
